The following letter was sent to a member of our community living with ALS:

Today, the FDA approved AMX0035, a new treatment for people living with ALS. AMX0035 is the first treatment funded by the iconic Ice Bucket Challenge to be approved by the FDA and it is because of the tireless work of advocates like you!

Over the past two years, the ALS community joined together to fight for access to AMX0035 for people living with ALS. We encouraged the FDA to act with urgency and to use flexibility to approve AMX0035. Over 14,000 people living with ALS, their loved ones, and advocates sent emails to the FDA urging the agency to approve this treatment. We also held several meetings with FDA and Amylyx, provided scientific and regulatory guidance, submitted written public comments, and ALS advocates and experts provided oral public comments during FDA Advisory Committee meetings.

The ALS Association’s support of AMX0035 began in 2016, with a $2.2 million donation to help develop and run a clinical trial of AMX0035. These funds came from ALS Ice Bucket Challenge donations. While today is an important milestone in the fight against ALS, we are also thinking of everyone we have lost along the way. Their courage and advocacy when faced with this devastating disease inspires our work every day.

Thank you for your tireless advocacy for people living with ALS and their loved ones. It is because of your actions that people living with ALS will now be able to access a new life-extending treatment.